Grannus Therapeutics is developing a first-in-class Hsp90β-selective inhibitor that eliminates the toxicity and dosing issues associated with previous pan-Hsp90 inhibitors. This targeted approach enhances treatment efficacy across multiple solid tumor types, providing healthcare professionals with a safer and more effective cancer therapy option.
Funding
$800K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Previous attempts to inhibit Hsp90 for cancer treatment have been unsuccessful due to on-target toxicities and disappointing efficacy, stemming from the use of pan-Hsp90 inhibitors that target all four isoforms of the protein. These non-selective inhibitors caused significant side effects, limiting their clinical viability.
Solution
Grannus Therapeutics is developing a first-in-class, Hsp90β-selective inhibitor designed to overcome the limitations of previous pan-Hsp90 inhibitors. By selectively targeting the Hsp90β isoform, Grannus's approach aims to eliminate the toxicity and dosing challenges associated with non-selective inhibition. This targeted therapy has demonstrated clean toxicity profiles and in-vivo efficacy, positioning it as a potential treatment option for patients with various solid tumors. The selective inhibition of Hsp90β offers a more refined approach to cancer therapy, potentially enhancing treatment efficacy while minimizing adverse effects.
Target Audience
The primary target audience includes healthcare professionals specializing in oncology and patients with solid tumors who may benefit from a more targeted and less toxic Hsp90 inhibitor.
Features
- Hsp90β-selective inhibition, avoiding off-target effects associated with pan-Hsp90 inhibitors.
- Demonstrated in-vivo efficacy across multiple solid tumor types.
- Clean toxicity profiles, addressing a key limitation of previous Hsp90-targeted therapies.